Insider Selling: Billiontoone (NASDAQ:BLLN) SVP Sells 1,416 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,416 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $120.00, for a total transaction of $169,920.00. Following the completion of the transaction, the senior vice president directly owned 33,552 shares in the company, valued at approximately $4,026,240. The trade was a 4.05% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The stock was sold at an average price of $101.47, for a total transaction of $287,363.04.

Billiontoone Stock Performance

Shares of Billiontoone stock traded up $2.35 on Wednesday, hitting $122.33. 687,667 shares of the company’s stock were exchanged, compared to its average volume of 479,467. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70. The company has a 50-day simple moving average of $94.21 and a 200-day simple moving average of $87.39. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.58 and a current ratio of 10.92. The stock has a market capitalization of $5.63 billion and a PE ratio of 222.42.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to analysts’ expectations of $95.81 million. The company’s revenue for the quarter was up 83.8% on a year-over-year basis. During the same quarter last year, the company earned ($0.39) earnings per share. As a group, equities analysts anticipate that Billiontoone, Inc. will post 0.93 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Adams Street Partners LLC purchased a new stake in shares of Billiontoone in the fourth quarter worth about $140,063,000. Baillie Gifford & Co. bought a new stake in Billiontoone in the 4th quarter worth approximately $103,786,000. Price T Rowe Associates Inc. MD bought a new stake in Billiontoone in the 4th quarter worth approximately $39,717,000. JPMorgan Chase & Co. purchased a new stake in shares of Billiontoone during the 4th quarter worth approximately $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone during the 1st quarter valued at approximately $29,179,000.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on BLLN shares. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Guggenheim assumed coverage on Billiontoone in a research note on Monday. They set a “buy” rating and a $125.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Weiss Ratings upgraded Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research note on Tuesday, June 23rd. Finally, BTIG Research reduced their price objective on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.00.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.